Abstract
The effects of daily administration of pentylenetetrazol (PTZ) on the rate of the development of kindled amygdaloid seizures (KAS) were tested in the rat. Rats were pretreated for 6 days with 25 mg/kg PTZ or normal saline 15 min. prior to each daily amygdaloid stimulation. The PTZ group exhibited fully developed KAS, including a maximal behavioral ranking (BR) and an afterdischarge duration (AD) of over 90 sec, in 3.8 ± 0.3 stimulations compared to 8.0 ± 0.6 stimulations (ave. ± SEM) for the saline controls. Within 10 min after dosing, PTZ consistently induced intermittent spiking of 5 sec or less in the EEG and behaviorally induced head nodding and sniffing. However, chemical kindling due to the 6 repetitive doses of PTZ was not observed. When the PTZ pretreatment was stopped on the 7th day, the BR and AD of the PTZ pretreatment group decreased from 187% and 161% of control values, respectively, to 118% and 100% of control. It appears that PTZ augments both the AD and BR of the developing KAS but does not accelerate the actual rate of the development of the KAS.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1225-1227 |
| Number of pages | 3 |
| Journal | Neuropharmacology |
| Volume | 20 |
| Issue number | 12 |
| DOIs | |
| State | Published - 1981 |
Fingerprint
ASJC Scopus subject areas
- Cellular and Molecular Neuroscience
- Drug Discovery
- Pharmacology
Cite this
Pentylenetetrazol augmentation of developing kindled amygdaloid seizures. / Bowyer, J. F.; Winters, W. D.; Albertson, Timothy E.
In: Neuropharmacology, Vol. 20, No. 12, 1981, p. 1225-1227.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pentylenetetrazol augmentation of developing kindled amygdaloid seizures
AU - Bowyer, J. F.
AU - Winters, W. D.
AU - Albertson, Timothy E
PY - 1981
Y1 - 1981
N2 - The effects of daily administration of pentylenetetrazol (PTZ) on the rate of the development of kindled amygdaloid seizures (KAS) were tested in the rat. Rats were pretreated for 6 days with 25 mg/kg PTZ or normal saline 15 min. prior to each daily amygdaloid stimulation. The PTZ group exhibited fully developed KAS, including a maximal behavioral ranking (BR) and an afterdischarge duration (AD) of over 90 sec, in 3.8 ± 0.3 stimulations compared to 8.0 ± 0.6 stimulations (ave. ± SEM) for the saline controls. Within 10 min after dosing, PTZ consistently induced intermittent spiking of 5 sec or less in the EEG and behaviorally induced head nodding and sniffing. However, chemical kindling due to the 6 repetitive doses of PTZ was not observed. When the PTZ pretreatment was stopped on the 7th day, the BR and AD of the PTZ pretreatment group decreased from 187% and 161% of control values, respectively, to 118% and 100% of control. It appears that PTZ augments both the AD and BR of the developing KAS but does not accelerate the actual rate of the development of the KAS.
AB - The effects of daily administration of pentylenetetrazol (PTZ) on the rate of the development of kindled amygdaloid seizures (KAS) were tested in the rat. Rats were pretreated for 6 days with 25 mg/kg PTZ or normal saline 15 min. prior to each daily amygdaloid stimulation. The PTZ group exhibited fully developed KAS, including a maximal behavioral ranking (BR) and an afterdischarge duration (AD) of over 90 sec, in 3.8 ± 0.3 stimulations compared to 8.0 ± 0.6 stimulations (ave. ± SEM) for the saline controls. Within 10 min after dosing, PTZ consistently induced intermittent spiking of 5 sec or less in the EEG and behaviorally induced head nodding and sniffing. However, chemical kindling due to the 6 repetitive doses of PTZ was not observed. When the PTZ pretreatment was stopped on the 7th day, the BR and AD of the PTZ pretreatment group decreased from 187% and 161% of control values, respectively, to 118% and 100% of control. It appears that PTZ augments both the AD and BR of the developing KAS but does not accelerate the actual rate of the development of the KAS.
UR - http://www.scopus.com/inward/record.url?scp=0019848856&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0019848856&partnerID=8YFLogxK
U2 - 10.1016/0028-3908(81)90069-1
DO - 10.1016/0028-3908(81)90069-1
M3 - Article
VL - 20
SP - 1225
EP - 1227
JO - Neuropharmacology
JF - Neuropharmacology
SN - 0028-3908
IS - 12
ER -